Chemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere

被引:41
作者
Campelj, Dean G. [1 ,2 ]
Goodman, Craig A. [2 ,3 ]
Rybalka, Emma [1 ,2 ,4 ]
机构
[1] Victoria Univ, Inst Hlth & Sport, Melbourne, Vic 8001, Australia
[2] Victoria Univ, Australian Inst Musculoskeletal Sci AIMSS, Inherited & Acquired Myopathy Program, St Albans, Vic 3021, Australia
[3] Univ Melbourne, Ctr Muscle Res CMR, Dept Physiol, Parkville, Vic 3010, Australia
[4] Univ Melbourne, Melbourne Med Sch, Dept Med Western Hlth, Melbourne, Vic 3021, Australia
关键词
cachexia; chemotherapy; exercise therapy; mitoprotection; muscle wasting; myopathy; pharmaceutical adjuvants; skeletal muscle; BREAST-CANCER PATIENTS; SKELETAL-MUSCLE ATROPHY; TUMOR-BEARING MICE; OXIDATIVE STRESS; EXERCISE PROTECTS; DOXORUBICIN ACTS; BODY-COMPOSITION; DIETARY NITRATE; DOUBLE-BLIND; RAT MODEL;
D O I
10.3390/cancers13143615
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary In addition to cancer-related factors, anti-cancer chemotherapy treatment can drive life-threatening body wasting in a syndrome known as cachexia. Emerging evidence has described the impact of several key chemotherapeutic agents on skeletal muscle in particular, and the mechanisms are gradually being unravelled. Despite this evidence, there remains very little research regarding therapeutic strategies to protect muscle during anti-cancer treatment and current global grand challenges focused on deciphering the cachexia conundrum fail to consider this aspect-chemotherapy-induced myopathy remains very much on the dark side of the cachexia sphere. This review explores the impact and mechanisms of, and current investigative strategies to protect against, chemotherapy-induced myopathy to illuminate this serious issue. Cancer cachexia is a debilitating multi-factorial wasting syndrome characterised by severe skeletal muscle wasting and dysfunction (i.e., myopathy). In the oncology setting, cachexia arises from synergistic insults from both cancer-host interactions and chemotherapy-related toxicity. The majority of studies have surrounded the cancer-host interaction side of cancer cachexia, often overlooking the capability of chemotherapy to induce cachectic myopathy. Accumulating evidence in experimental models of cachexia suggests that some chemotherapeutic agents rapidly induce cachectic myopathy, although the underlying mechanisms responsible vary between agents. Importantly, we highlight the capacity of specific chemotherapeutic agents to induce cachectic myopathy, as not all chemotherapies have been evaluated for cachexia-inducing properties-alone or in clinically compatible regimens. Furthermore, we discuss the experimental evidence surrounding therapeutic strategies that have been evaluated in chemotherapy-induced cachexia models, with particular focus on exercise interventions and adjuvant therapeutic candidates targeted at the mitochondria.
引用
收藏
页数:27
相关论文
共 233 条
[51]  
Chen Meng-Chuan, 2018, Oncotarget, V9, P19584, DOI 10.18632/oncotarget.24680
[52]   Combined administration of fucoidan ameliorates tumor and chemotherapy-induced skeletal muscle atrophy in bladder cancer-bearing mice [J].
Chen, Meng-Chuan ;
Hsu, Wen-Lin ;
Hwang, Pa-An ;
Chen, Yen-Lin ;
Chou, Tz-Chong .
ONCOTARGET, 2016, 7 (32) :51608-51618
[53]   Supplementation of Magnolol Attenuates Skeletal Muscle Atrophy in Bladder Cancer-Bearing Mice Undergoing Chemotherapy via Suppression of FoxO3 Activation and Induction of IGF-1 [J].
Chen, Meng-Chuan ;
Chen, Yen-Lin ;
Lee, Chi-Feng ;
Hung, Chih-Huang ;
Chou, Tz-Chong .
PLOS ONE, 2015, 10 (11)
[54]   Abnormal muscle afferent function in a model of Taxol chemotherapy-induced painful neuropathy [J].
Chen, Xiaojie ;
Green, Paul G. ;
Levine, Jon D. .
JOURNAL OF NEUROPHYSIOLOGY, 2011, 106 (01) :274-279
[55]   Collateral damage in cancer chemotherapy - Oxidative stress in nontargeted tissues [J].
Chen, Yumin ;
Jungsuwadee, Paiboon ;
Vore, Mary ;
Butterfield, D. Allan ;
Clair, Daret K. St. .
MOLECULAR INTERVENTIONS, 2007, 7 (03) :147-156
[56]   SIRT1 activation by pterostilbene attenuates the skeletal muscle oxidative stress injury and mitochondrial dysfunction induced by ischemia reperfusion injury [J].
Cheng, Yedong ;
Di, Shouyin ;
Fan, Chongxi ;
Cai, Liping ;
Gao, Chao ;
Jiang, Peng ;
Hu, Wei ;
Ma, Zhiqiang ;
Jiang, Shuai ;
Dong, Yushu ;
Li, Tian ;
Wu, Guiling ;
Lv, Jianjun ;
Yang, Yang .
APOPTOSIS, 2016, 21 (08) :905-916
[57]   HSP72 protects against obesity-induced insulin resistance [J].
Chung, Jason ;
Nguyen, Anh-Khoi ;
Henstridge, Darren C. ;
Holmes, Anna G. ;
Chan, M. H. Stanley ;
Mesa, Jose L. ;
Lancaster, Graeme I. ;
Southgate, Robert J. ;
Bruce, Clinton R. ;
Duffy, Stephen J. ;
Horvath, Ibolya ;
Mestril, Ruben ;
Watt, Matthew J. ;
Hooper, Philip L. ;
Kingwell, Bronwyn A. ;
Vigh, Laszlo ;
Hevener, Andrea ;
Febbraio, Mark A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (05) :1739-1744
[58]  
Cohen MH, 2001, J CLIN ONCOL, V19, P1229, DOI 10.1200/JCO.2001.19.4.1229
[59]   Chemotherapy-induced muscle wasting: an update [J].
Coletti, Dario .
EUROPEAN JOURNAL OF TRANSLATIONAL MYOLOGY, 2018, 28 (02) :153-157
[60]   Cisplatin-Induced Skeletal Muscle Dysfunction: Mechanisms and Counteracting Therapeutic Strategies [J].
Conte, Elena ;
Bresciani, Elena ;
Rizzi, Laura ;
Cappellari, Ornella ;
De Luca, Annamaria ;
Torsello, Antonio ;
Liantonio, Antonella .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (04)